TABLE 2.
DEMOGRAPHIC AND CLINICAL CHARACTERISTICS OF SUBJECTS WITH LUNG DISEASE TESTED BY ANTI-HEAT SHOCK PROTEIN 70 ELISA
| IPF ELISA Cohort | ILD (Non-IPF) ELISA Cohort | |
| n | 121 | 51 |
| Age, yr | 69 ± 1 | 60 ± 2* |
| Sex, % male | 74 | 43* |
| Lung biopsy, % | 55 | 63 |
| FVC % predicted | 61 ± 2 | 71 ± 3* |
| DlCO % predicted | 47 ± 2 | 50 ± 3 |
| Smoking history, % | 53 | 52 |
| Immunosuppressants, % | 19 | 25 |
| Race, % African American | 0 | 8* |
Definition of abbreviations: DlCO = diffusing capacity for carbon monoxide; ILD = interstitial lung disease; IPF = idiopathic pulmonary fibrosis.
Lung biopsy describes the percentage of subjects in each population who had pulmonary histological assessments. In all cases these showed characteristic pathological features of IPF (21, 22). Smoking history denotes subjects with ≥5 pack-year history of cigarette smoking. Immunosuppressants denote subjects taking any single agent or various permutations of prednisone (5–20 mg/d), azathioprine, IFN-γ, mycophenolate, or tacrolimus.
P ≤ 0.002. Specific diagnoses of the subjects with ILD are detailed in online supplement E3.